Hep C Outreach Program Launched in Geelong
Hepatitis C: A New Era of Outreach and Eradication in 2025
Table of Contents
By Dr. Jennifer Chen
As we navigate the mid-2020s, the fight against Hepatitis C (HCV) is entering a pivotal new phase. On July 14, 2025, the Geelong Advertiser highlighted a notable development: a new outreach program specifically targeting undiagnosed cases of Hepatitis C. This initiative, while localized, represents a broader, crucial shift in public health strategy – one that prioritizes proactive identification and treatment to achieve eventual eradication. This article aims to serve as a foundational, evergreen resource, demystifying Hepatitis C, outlining the latest advancements in its management, and underscoring the vital importance of these new outreach efforts in our ongoing battle against this persistent virus.
Understanding Hepatitis C: The Silent Threat
Hepatitis C is a viral infection that primarily affects the liver. It’s caused by the Hepatitis C virus (HCV). For many years, HCV was a silent threat, often progressing without noticeable symptoms until significant liver damage had occurred. This insidious nature made early diagnosis and intervention challenging, leading to a ample burden of chronic liver disease, including cirrhosis and liver cancer.
How is Hepatitis C Transmitted?
Understanding transmission is key to prevention and control. HCV is primarily transmitted through blood-to-blood contact. This can occur in several ways:
Sharing Needles and Syringes: This is the most common mode of transmission, especially among individuals who inject drugs.
Unsafe Medical procedures: In the past, inadequate sterilization of medical equipment, especially in healthcare settings in developing countries, contributed to transmission.
Blood Transfusions and Organ Transplants: Before widespread screening of blood and organ donations (which became standard in many developed countries in the early 1990s), this was a significant route of infection.
Needlestick Injuries: Healthcare workers are at risk of accidental exposure through needlestick injuries.
Sexual Transmission: While less common than blood-to-blood transmission, sexual contact can transmit HCV, particularly among individuals with HIV, multiple partners, or those who engage in rough sex.
Mother-to-Child Transmission: A small percentage of infants born to mothers with HCV can contract the virus during childbirth.
It’s important to note that HCV is not typically spread through casual contact,such as hugging,kissing,sharing utensils,or coughing and sneezing.
The Progression of Hepatitis C
Once infected, the virus can lead to two phases:
Acute Hepatitis C: This is the initial stage, typically occurring within the frist six months after infection. Many people with acute HCV have no symptoms. If symptoms do occur, they can include fatigue, nausea, abdominal pain, loss of appetite, jaundice (yellowing of the skin and eyes), and dark urine. In some cases, the body can clear the virus during this phase.
Chronic hepatitis C: If the body does not clear the virus within six months, it becomes chronic.Chronic HCV can persist for decades, frequently enough without symptoms. Over time, the virus can cause inflammation and scarring of the liver, leading to fibrosis, cirrhosis (severe scarring), liver failure, and hepatocellular carcinoma (liver cancer).
For decades, treatment for Hepatitis C was challenging, involving lengthy courses of interferon and ribavirin, which had significant side effects and lower cure rates. The landscape of HCV treatment was revolutionized with the advent of Direct-Acting Antivirals (DAAs).
What are DAAs?
DAAs are a class of medications that directly target specific proteins essential for HCV replication. They work by inhibiting the virus’s ability to multiply within the body. These drugs are highly effective, well-tolerated, and can cure Hepatitis C in over 95% of cases with a treatment duration typically ranging from 8 to 12 weeks.
The Impact of DAAs
The introduction of DAAs has transformed Hepatitis C from a chronic,potentially life-threatening illness into a curable disease for most individuals. This has profound implications for public health, reducing the incidence of cirrhosis, liver failure, and liver cancer, and ultimately saving lives. The World Health Organization (WHO) has set aspiring goals for HCV elimination by